This company has been marked as potentially delisted and may not be actively trading. NYSE:ARA American Renal Associates (ARA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About American Renal Associates Stock (NYSE:ARA) 30 days 90 days 365 days Advanced Chart Get ARA alerts:Sign Up Key Stats Today's Range$11.33▼$11.5250-Day Range$11.46▼$11.5252-Week Range$5.57▼$11.98Volume9,831 shsAverage Volume106,940 shsMarket Capitalization$397.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAmerican Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.Read More… Receive ARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for American Renal Associates and its competitors with MarketBeat's FREE daily newsletter. Email Address ARA Stock News HeadlinesBayer's Kerendia® (finerenone) Included in Latest Focused Guideline Clinical Updates from European Society of CardiologyAugust 31, 2023 | benzinga.comAnemia in Chronic Kidney Disease (Renal Anemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 UpdateFebruary 22, 2023 | finance.yahoo.comThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?May 5, 2025 | Timothy Sykes (Ad)Liberation From Renal Replacement Therapy and Early Initiation to Be Supported by The Kidney Function Biomarker Proenkephalin A 119-159 (penKid)January 11, 2023 | finance.yahoo.comContinuous Renal Replacement Therapy Global Market Report 2022: Rising Prevalence of Acute Kidney Injuries Drives DemandJanuary 2, 2023 | finance.yahoo.comDalian Atkinson: Footballer killed hours before renal treatmentOctober 7, 2022 | bbc.comARA Appoints James Myers Vice President, Program Innovation and GrowthJune 22, 2022 | finance.yahoo.comAmerican Renal Associates Holdings, Inc. NewsJune 20, 2022 | thestreet.comSee More Headlines ARA Stock Analysis - Frequently Asked Questions How were American Renal Associates' earnings last quarter? American Renal Associates Holdings, Inc. (NYSE:ARA) issued its quarterly earnings data on Wednesday, November, 11th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.06 by $0.09. The business earned $209.69 million during the quarter, compared to the consensus estimate of $211.50 million. American Renal Associates had a negative net margin of 2.04% and a negative trailing twelve-month return on equity of 3.56%. When did American Renal Associates IPO? American Renal Associates (ARA) raised $161 million in an initial public offering (IPO) on Thursday, April 21st 2016. The company issued 7,500,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers. What other stocks do shareholders of American Renal Associates own? Based on aggregate information from My MarketBeat watchlists, some other companies that American Renal Associates investors own include Zevra Therapeutics (KMPH), Madrigal Pharmaceuticals (MDGL), Exelixis (EXEL), Gilead Sciences (GILD), Spectrum Pharmaceuticals (SPPI), AbbVie (ABBV) and Bristol-Myers Squibb (BMY). Company Calendar Last Earnings11/11/2020Today5/05/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Miscellaneous Health & Allied Services Sub-IndustryN/A Current SymbolNYSE:ARA CIK1498068 Webwww.americanrenal.com Phone978-922-3080FaxN/AEmployees4,977Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.26 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,790,000.00 Net Margins-2.04% Pretax MarginN/A Return on Equity-3.56% Return on Assets-0.24% Debt Debt-to-Equity Ratio7.54 Current Ratio1.05 Quick Ratio1.02 Sales & Book Value Annual Sales$822.52 million Price / Sales0.48 Cash Flow$1.69 per share Price / Cash Flow6.80 Book Value$2.59 per share Price / Book4.45Miscellaneous Outstanding Shares34,543,000Free FloatN/AMarket Cap$397.94 million OptionableOptionable Beta1.11 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NYSE:ARA) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding American Renal Associates Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share American Renal Associates With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.